



CT-Cann2023

# The 2<sup>nd</sup> International Congress on Clinical Trials on Cannabis

15-16 February 2023, London, UK

Program Book

Endorsed by:



**Bio events**  
Sharing Biomed Knowledge

Join the discussion

 @BiomedSharing

#CTCANN2023

## Congress Venue

### Hilton London Canary Wharf

South Quay, Marsh Wall, London E14 9SH, UK

Tel: +44 20 3002 2300

## Registration Desk

The Registration Desk will be open during the following times:

Wednesday, 15 February                      07:45 – 17:20

Thursday, 16 February                         08:00 – 17:00

## Participants Badge

Upon arrival you will receive your name badge at the registration desk. Scan the QR code on the badge to download/view the program book. You are kindly requested to wear your badge during all congress sessions and events.

## Wifi

Free WIFI is available at the congress. Please be aware that public WIFI capacity is limited.

Select network: **Hilton Honors**, click on 'I have a Promotional Code' and enter code **Canary2023**.

## Congress Sessions

All sessions will take place in the Quayside Suite halls.

## Posters

Posters will be displayed in the Quayside Suite foyer for the duration of the congress.

## Refreshments

Coffee and light buffet lunch will be served in the Quayside Suite foyer at the times indicated in the program.

## Safety And Security

Please do not leave any bags or suitcases unattended at any time, whether inside or outside session halls. The congress organisers cannot accept liability for personal accidents or loss of/damage to private property of participants of CT-Cann2023.

## Congress Secretariat

ilana@bioevents-congress.com

Tel: +44 (0)203 051 4032 ext 525 / M: +44 (0)7971 519 961

## Wednesday, 15 February 2023

<b>07:45</b>	<b>Registration</b>
09:15	<b>Congress Opening &amp; Welcome</b> <i>Haggai Sharon, Israel, Dedi Meiri, Israel – Congress Chairs</i>
<b>09:30-10:30</b>	<b>Session I: Prescribing Medical Cannabis</b> <i>Chair: Haggai Sharon, Israel</i>
09:30-10:00	<b>Prescribing medical cannabis in the UK – Where are we and what are the main challenges?</b> <i>Mike Barnes, UK</i>
10:00-10:30	<b>Risk Stratification in Medical Cannabis – what the clinician should know</b> <i>Haggai Sharon, Israel</i>
<b>10:30-11:00</b>	<b>Coffee Break</b>
11:00-11:45	<b>Introduction</b> <i>Dedi Meiri, Israel</i>  <b>Keynote Presentation:</b> <b>The Gold Standard for the Green Rush: Insights from Clinical Trials from the MIND Program</b> <i>Staci Gruber, USA</i>
<b>11:45-12:45</b>	<b>Session II: Emerging Clinical Applications I</b> <i>Chair: Mike Barnes, UK</i>
11:45-12:15	<b>Chemotherapy induced polyneuropathy</b> <i>Marie Fallon, UK</i>
12:15-12:45	<b>Acute pain</b> <i>Elyad Davidson, Israel</i>
<b>12:45-13:45</b>	<b>Lunch Break</b>
<b>13:45-15:15</b>	<b>Session III: Leading Industry</b> <i>Chair: Roei Zerahia, Israel</i>
13:45-14:05	<b>Advancing the cannabinoid scientific research landscape</b> <i>Terry O'Regan, Canada</i>
14:05-14:25	<b>Addressing the challenge of CBD bioavailability: modulating physical properties of selected formulations in order to enhance in-vitro bioaccessibility and in-vivo pharmacokinetic performance</b> <i>Alexandru Zabara, Switzerland</i>

14:25-14:35	<b>Q&amp;A</b> <i>Terry O'Regan, Canada</i> <i>Alexandru Zabara, Switzerland</i>
14:35-14:50	<b>Script Assist – Solving the challenges facing independent prescribers of medical cannabis</b> <i>Arjun Rajyagor, UK</i>
<b>14:50-15:20</b>	<b>Coffee Break</b>
15:20-16:20	<b>Session IV: Regulatory</b> <i>Chair: Silviu Brill, Israel</i>
15:20-15:50	<b>Regulation in the pharma industry – Making quality APIs for research</b> <i>Henrik Uth, Denmark</i>
15:50-16:20	<b>Driving – the dilemma and current evidence</b> <i>Silviu Brill, Israel</i>
16:20-17:20	<b>Original Research Presentations 1</b> <i>Chair: Staci Gruber, USA</i>
16:20-16:30	<b>Phytocannabinoids and Periodontal Inflammation</b> <i>Jan Vacek, Czech Republic</i>
16:30-16:40	<b>Questioning Assumptions about the Abuse Potential of Medical Cannabis and Cannabinoids: A Critical Review and Rationale and Focus for Clinical Trials</b> <i>Peter Pressman, USA</i>
16:40-16:50	<b>Stoned and rejected: a naturalistic study of the impact of social exclusion and acute cannabis use on sexual arousal, sexual inhibitions and risky sexual behavior</b> <i>Sharon Rabinovitz, Israel</i>
16:50-17:00	<b>The Impact of Cannabidiol Treatment on Brain Function and Metabolism of Patients with a Psychotic Disorder</b> <i>Matthijs Bossong, Netherlands</i>
17:00-17:10	<b>“Flower Power”: Controlled Inhalation of Chemotype I Cannabis Flos Improves Health-Related Quality of Life and Alleviates Symptoms of Chronic Pain and Anxiety in UK Patients</b> <i>Guillermo Moreno Sanz, Spain</i>
17:10-17:20	<b>Novel Medical Cannabis Regimens in the Canadian Veteran Population: Reducing Negative Side Effects of Polypharmacy and Optimizing Outcomes</b> <i>Celeste Thirlwell, Canada</i>

## Thursday, 16 February 2023

08:00	<b>Registration</b>
09:00-10:30	<b>Session V: Non RCT Methodologies</b> <i>Chair: Dedi Meiri, Israel</i>
09:00-09:30	<b>Preclinical studies investigating the endocannabinoid system in reciprocal interactions between pain, cognition and emotion</b> <i>David Finn, Ireland</i>
09:30-10:00	<b>From a complex plant to clinical trials</b> <i>Dedi Meiri, Israel</i>
10:00-10:30	<b>Planning and running a high-quality clinical registry</b> <i>Michael Thomas Lynskey, UK</i>
10:30-11:00	<b>Coffee Break</b>
11:00-12:30	<b>Session VI: Emerging clinical applications II</b> <i>Chair: Janet Schloss, Australia</i>
11:00-11:30	<b>Headache disorders</b> <i>Amnon Mosek, Israel</i>
11:30-12:00	<b>Long Covid</b> <i>Elizabeth Iveson, UK</i>
12:00-12:30	<b>A phase 2 clinical trial in patients with high grade gliomas</b> <i>Janet Schloss, Australia</i>
12:30-13:30	<b>Lunch Break</b>
13:30-14:10	<b>Original Research Presentations 2</b> <i>Chair: Dedi Meiri, Israel</i>
13:30-13:40	<b>Study of Antimicrobial Activity of Hemp Extract Seed Oil against Staphylococcus Pseudintermedius and Pseudomonas Aeruginosa Strains Isolated from Pyoderma and External Otitis in Dogs</b> <i>Valeria Toppi, Italy</i>
13:40-13:50	<b>The chemotypes I and III of Cannabis sativa L., induce distinct types of cell death (apoptosis / necrosis) in human leukemic cell lines</b> <i>Sandra Paola Santander Gonzalez, Colombia</i>

13:50-14:00	<p><b>Safety and Feasibility of Administration of an Oral Cannabis Preparation in The Preoperative Period in Breast and Oral Cavity Cancer</b>  <i>Joshi Shalaka, India</i></p>
14:00-14:10	<p><b>Randomised, Placebo-Controlled, Double-Blind Studies of Medicinal Cannabis for Symptom Management in Patients with Advanced Cancer</b>  <i>Janet Hardy, Australia</i></p>
14:10-15:40	<p><b>Session VII: UK in focus</b>  <i>Chair: Arun Bhaskar, UK</i></p>
14:10-14:40	<p><b>Educating clinicians – setting up educational resources and networking platforms</b>  <i>Niraj Singh, UK</i></p>
14:40-15:10	<p><b>Practicalities of prescribing cannabis in the UK</b>  <i>Arun Bhaskar, UK</i></p>
15:10-15:40	<p><b>Navigating the UK regulations and governance requirements for cannabis prescribers</b>  <i>Arjun Rajyagor, UK</i></p>
<b>15:40-16:10</b>	<b>Coffee Break</b>
16:10-17:00	<p><b>Session VIII: A round table – clinicians and researchers</b>  <i>Chair: Haggai Sharon, Israel</i></p>
	<p><b>Prescribing cannabis – a practical Q&amp;A with expert clinicians</b>  <i>Haggai Sharon, Israel and Arun Bhaskar, UK – Chronic Pain</i>  <i>Niraj Singh, UK – Psychiatry</i>  <i>Amnon Mosek, Israel – Neurology</i>  <i>Marie Fallon, UK – Palliative Care</i></p>
<b>17:00</b>	<p><b>Congress Closing Remarks</b>  <i>Haggai Sharon, Israel, Dedi Meiri, Israel – Congress Chairs</i></p>



# Poster Presentations

Posters will be on display for the duration of the congress.

Posters may be displayed from 07:45 on Wednesday, 15 February and must be removed after sessions on Thursday 16 February. The congress organizers cannot be responsible for posters not removed by this time.

**Please mount your poster on the poster board number assigned to you.**

Board No.	Abstract Topic & Title
<b>Phytocannabinoid study – strains, chemovars, entourage and molecules</b>	
1	<b>The Nematode <i>C. elagans</i> as an Objective Test System to Study Putative Entourage Effects of Cannabis</b> <i>Henrie Korthout, Monique Es-Remers, Jesus Arellano Spadaro, Eefje Poppelaars, Hye Kyong Kim, Marieke Van Haaster, Marjolein Wildwater, Netherlands</i>
2	<b>Study of Antimicrobial Activity of Hemp Extract Seed Oil against <i>Staphylococcus Pseudintermedius</i> and <i>Pseudomonas Aeruginosa</i> Strains Isolated from Pyoderma and External Otitis in Dogs</b> <i>Valeria Toppi, Elisa Rampacci, Giorgia Della Rocca, Alessandra Di Salvo, Marina De Benedetti, Patrizia Casagrande Proietti, Italy</i>
3	<b>Delta9-tetrahydrocannabinol conserves cardiovascular functions in a rat model of endotoxemia: involvement of endothelial molecular mechanisms and oxidative-nitrative stress</b> <i>Balint Banyai, Zsuzsanna Miklós, Csaba Répás, Johnny Johnsen, Eszte Horváth, Rita Benkő, Hungary</i>
4	<b>Improving the solubility of cannabinoids as a way to increase their bioavailability</b> <i>Anna Stasiłowicz-Krzemien, Szymon Sip, P. Szulc, Judyta Cielecka-Piontek, Poland</i>
<b>Pharmacokinetics and pharmacodynamics of cannabinoids</b>	
5	<b>The Impact of Cannabidiol Treatment on Brain Function and Metabolism of Patients with a Psychotic Disorder</b> <i>Ruben Van Boxel, Shiral Gangadin, Albert Batalla, Matthijs Bossong, Netherlands</i>
<b>Clinical cannabinoid therapy across medical specialties; Pain, Gastroenterology, Palliative Care, Psychiatry and Neurology</b>	
6	<b>Cannabis-Based Medicinal Products in the Management of Emotionally Unstable Personality Disorder (EUPD): A Narrative Review and Case Series</b> <i>Waseem Sultan, Anup Mathew, Matt RB Brown, Guillermo Moreno Sanz, UK/Spain</i>

**7** Effects of Oral Cannabinoids on Systemic Inflammation and Viral Reservoirs in People with HIV on Antiretroviral Therapy: Results of the CTNPT 028 Clinical Trial

*Eve Comeau, Ralph Sydney Mboumba Bouassa, Amelie Pagliuzza, Suzanne Samarani, Judy Needham, Joel Singer, Terry Lee, Florian Bobeuf, Claude Vertzagias, Giada Sebastiani, Shari Margolese, Enrico Mandarino, Marina Klein, Bertrand Lebouche, Jean-Pierre Routy, Nicolas Chomont, Mohammad-Ali Jenabian, Cecilia Costiniuk, Canada*

## New designs for cannabis clinical trials (including pragmatic trials and n=1)

**8** The C4EB study - Transvamix® (10% THC / 5% CBD) to treat chronic pain in Epidermolysis Bullosa: A protocol for an explorative randomized, placebo controlled, and double blind intervention crossover study

*Nicholas Schröder, Peter Sörös, Remco Renken, Karin Vermeulen, José Duipmans, Maria Bolling, André Wolff, Netherlands*

## Observational / Epidemiological studies: findings, interpretations, plans

**9** "Flower Power": Controlled Inhalation of Chemotype I Cannabis Flos Improves Health-Related Quality of Life and Alleviates Symptoms of Chronic Pain and Anxiety in UK Patients

*Guillermo Moreno Sanz, Alvaro Madiedo, Michael Lynskey Michael, Matt RB Brown, Spain/UK*

## Phase 2/3/4 study findings and designs (including special populations)

**10** Randomised, Placebo-Controlled, Double-Blind Studies of Medicinal Cannabis for Symptom Management in Patients with Advanced Cancer

*Janet Hardy, Ristan Greer, Taylan Gurgenci, Phillip Good, Australia*

## Meta- and composite- analyses: findings and methodology

**11** Clinical research evidence supporting administration and dosing recommendations of medicinal cannabis as analgesic in cancer patients

*Catalina Christensen, Morten Allesø, Martin Rose, Claus Cornett, Denmark*

**12** Patient Experiences, Attitudes, and Beliefs Towards the Use of Medicinal Cannabis: A Scoping Review

*Frederik Rosenbaek, Jessica Joan Williams, Sif Schmidt Stewart-Ferrer, Line Bjørnskov Pedersen, Frans Boch Waldorff, Jens Søndergaard, Jesper Bo Nielsen Jesper, Helle Riisgaard, Denmark*



## Assessing safety and adverse events of cannabinoid medications

- |    |  |
|----|--|
| 13 | <p>Inhaled <math>\Delta^9</math>-Tetrahydrocannabinol (THC) is Without Effect on Respiration and Does Not Enhance Oxycodone-Induced Respiratory Depression: A Randomized Controlled Trial in Healthy Volunteers<br/><i>Cornelis J. van Dam, Rutger van der Schrier, Monique van Velzen, Maarten van Lemmen, Pieter Simons., Kiki WK Kuijpers, Simone Jansen, Mikael Kowal, Erik Olofsen, Cornelis Kramers, Albert Dahan, Marieke Niesters, Netherlands</i></p> |
| 14 | <p>Questioning Assumptions about the Abuse Potential of Medical Cannabis and Cannabinoids: A Critical Review and Rationale and Focus for Clinical Trials<br/><i>Peter Pressman, Julia Hoeng, Wallace A. Hayes, USA/Switzerland</i></p>   |
| 15 | <p>Safety Assessment in Rats after Chronic Exposure to Cannabidiol and Cannabigerol<br/><i>Jan Vacek, Czech Republic</i></p>   |

## With Thanks To Our Sponsors

### Gold Sponsors



### Sponsor





Where  
others see  
**cannabinoid  
APIs**

we see  
**unlimited  
potential**

Because advancing health takes more than ingredients -  
**it takes a reliable innovation partner**

Join us  
Conference Session:  
Leading Industry  
15 February



Terry O'Regan, President Brains Bio  
**ADVANCING THE CANNABINOID SCIENTIFIC LANDSCAPE**

Alexandru Zabara, Innovation Manager Pharma DSM  
**ADDRESSING THE CHALLENGE OF CBD BIOAVAILABILITY**



For more information visit  
[www.dsm.com/cbd-apis](http://www.dsm.com/cbd-apis)